Ipsen's Cabometyx MAA approved, Exelixis takes home $50M
Ipsen Group (Euronext:IPN; Pink:IPSEY) said the European Commission approved an MAA for Cabometyx cabozantinib to treat first-line renal cell carcinoma, triggering a $50 million milestone payment to partner Exelixis Inc. (NASDAQ:EXEL). Cabometyx will now be indicated to treat intermediate or poor-risk patients with advanced RCC.
FDA added first-line RCC to Cabometyx's label in December 2017. Ipsen holds the drug's rights outside the U.S. and Japan from Exelixis...
BCIQ Target Profiles
AXL receptor tyrosine kinase (AXL) (UFO)
Vascular endothelial growth factor (VEGF) receptor 1 (FLT1) (VEGFR-1)
Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1)
Vascular endothelial growth factor (VEGF) receptor 3 (FLT4) (VEGFR-3)
c-Met receptor tyrosine kinase (c-MET) (MET) (HGFR) (c-Met proto-oncogene)